Service integration: Opportunities to expand access to antiretroviral therapy for people who inject drugs in Tanzania

Journal of the International AIDS Society

Volumn 18, Issue 1, 2015, Pages

  Lambdin, Barrot H ^a,b,c   Mbwambo, Jessie K ^d   Josiah, Robert M ^e   Bruce, Robert D ^f,g  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e MINISTRY OF HEALTH AND SOCIAL WELFARE   (Tanzania)

^f South Central Rehabilitation Center   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV AIDS; Implementation science; Methadone; People who inject drugs; Service integration

Indexed keywords

DIAMORPHINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; METHADONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

BIOAVAILABILITY; BLOOD SAMPLING; COMMUNITY CARE; DRUG ADMINISTRATION; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL DEPARTMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; INFECTION PREVENTION; LABORATORY TEST; LAW ENFORCEMENT; MEDICAL INFORMATICS; MEDICAL SERVICE; NOTE; PATIENT COUNSELING; POINT OF CARE TESTING; POSITIVE PEOPLE WHO INJECT DRUG; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REMINDER SYSTEM; SELF INJECTION; SURVIVAL RATE; TANZANIA; VIRUS LOAD; COMPLICATION; HEALTH CARE DELIVERY; HIV INFECTIONS; POINT OF CARE SYSTEM; SUBSTANCE ABUSE;

ANTI-HIV AGENTS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; POINT-OF-CARE SYSTEMS; SUBSTANCE ABUSE, INTRAVENOUS; TANZANIA;

EID: 84938272749     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.18.1.19936     Document Type: Note

References (23)

1. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815-26.
2. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-63.
3. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505.
4. Ogbuagu O, Bruce RD. Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups. Curr HIV/AIDS Rep. 2014;11(4):505-12.
5. Bruce RD. Is it time for treatment as prevention among people who inject drugs? J Acquir Immune Defic Syndr. 2013;63(5):545-7.
6. Gruskin S, Ferguson L, Alfven T, Rugg D, Peersman G. Identifying structural barriers to an effective HIV response: using the National Composite Policy Index data to evaluate the human rights, legal and policy environment. J Int AIDS Soc. 2013;16(1):18000, doi: http://dx.doi.org/10.7448/IAS.16.1.18000
7. OSI. Lowering the threshold: models of accessible methadone and buprenorphine treatment (English). OSI; 2010 [cited 2015 Mar 2]. Available from: http://www.opensocietyfoundations.org/sites/default/files/lowering-thethreshold-20100311.pdf
8. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010; 376(9738):355-66.
9. Sarang A, Rhodes T, Sheon N. Systemic barriers accessing HIV treatment among people who inject drugs in Russia: a qualitative study. Health Pol Plan. 2013;28(7):681-91.
10. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010; 375(9719):1014-28.
11. Ross MW, McCurdy SA, Kilonzo GP, Williams ML, Leshabari MT. Drug use careers and blood-borne pathogen risk behavior in male and female Tanzanian heroin injectors. Am J Trop Med Hyg. 2008;79(3):338-43.
12. UNODC. The global Afghan opium trade: a threat assessment. UNODC; 2011 [cited 2015 Mar 2]. Available from: https://www.unodc.org/documents/data-and-analysis/Studies/Global-Afghan-Opium-Trade-2011-web.pdf
13. Tanzania National AIDS Control Program. Consensus estimates on key population size and HIV prevalence in Tanzania. Dar es Salaam, Tanzania; 2014 [cited 2015 Mar 2]. Available from: http://www.healthpolicyproject.com/pubs/391-FORMATTEDTanzaniaKPconsensusmtgreport.pdf
14. TACAIDS, ZAC, NBS, OCGS, ICF International, ORC Macro. Tanzania HIV/AIDS and Malaria Indicator Survey. 2013 [cited 2015 Mar 2]. Available from: http://dhsprogram.com/pubs/pdf/AIS11/AIS11.pdf
15. Human Rights Watch. ''Treat Us Like Human Beings'' discrimination against sex workers, sexual and gender minorities and people who use drugs in Tanzania. 2013 [cited 2015 Mar 2]. Available from: http://www.hrw.org/reports/2013/06/18/treat-us-human-beings-0
16. Amon JJ. The political epidemiology of HIV. J Int AIDS Soc. 2014;17:19327, doi: http://dx.doi.org/10.7448/IAS.17.1.19327
17. Lambdin BH, Masao F, Chang O, Kaduri P, Mbwambo J, Magimba A, et al. Methadone treatment for HIV prevention-feasibility, retention, and predictors of attrition in Dar es Salaam, Tanzania: a retrospective cohort study. Clin Infect Dis. 2014;59(5):735-42.
18. Tran OC, Bruce RD, Masao F, Ubuguyu O, Sabuni N, Mbwambo J, et al. Linkage to CD4 screening among methadone clients living with HIV in Dar es Salaam, Tanzania. J Acquir Immune Defic Syndr. 2015;69:e43-8.
19. Lambdin BH, Cheng B, Peter T, Mbwambo J, Apollo T, Dunbar M, et al. Implementing implementation science: an approach for HIV prevention, care and treatment programs. Curr HIV Res. 2015;13(3):244-6.
20. Sweeney S, Obure CD, Terris-Prestholt F, Darsamo V, Michaels-Igbokwe C, Muketo E, et al. The impact of HIV/SRH service integration on workload: analysis from the Integra Initiative in two African settings. Hum Resour Health. 2014;12:42.
21. Jani IV, Sitoe NE, Alfai ER, Chongo PL, Quevedo JI, Rocha BM, et al. Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study. Lancet. 2011;378(9802):1572-9.
22. Mtapuri-Zinyowera S, Chideme M, Mangwanya D, Mugurungi O, Gudukeya S, Hatzold K, et al. Evaluation of the PIMA point-of-care CD4 analyzer in VCT clinics in Zimbabwe. J Acquir Immune DeficSyndr. 2010;55(1):1-7.
23. Catalani C, Philbrick W, Fraser H, Mechael P, Israelski DM. mHealth for HIV treatment & prevention: a systematic review of the literature. Open AIDS J. 2013;7:17-41.